In methionine- and choline-deficient diet-induced NASH in male C57BL/6 mice, treatment with EGCG (25, 50, and 100 mg/kg BW, i.p., daily, 4 weeks) inhibited the mRNA expressions of TGF-β, COL I-α1, tissue inhibitor of metalloproteinases 1/TIMP-1, and α- SMA, as well as the phosphorylation of SAMD2 and SMAD3 in the liver and HSCs (LX-2 cells), suggesting that EGCG could ameliorate liver fibrosis in NAFLD by targeting the TGF-β/SMAD pathway [136]. This evidence concerns the gene TGFB1 and metabolic dysfunction-associated steatotic liver disease.